CY1110379T1 - Συνθεση που περιλαμβανει φορμοτερολη και ενα γλυκοκορτικοστεροειδες - Google Patents

Συνθεση που περιλαμβανει φορμοτερολη και ενα γλυκοκορτικοστεροειδες

Info

Publication number
CY1110379T1
CY1110379T1 CY20081100387T CY081100387T CY1110379T1 CY 1110379 T1 CY1110379 T1 CY 1110379T1 CY 20081100387 T CY20081100387 T CY 20081100387T CY 081100387 T CY081100387 T CY 081100387T CY 1110379 T1 CY1110379 T1 CY 1110379T1
Authority
CY
Cyprus
Prior art keywords
gluccortosteroid
composition containing
containing formoterol
formoterol
copd
Prior art date
Application number
CY20081100387T
Other languages
English (en)
Inventor
Eva Trofast
Karin Malmqvist-Granlund
Per-Gunnar Nilsson
Kyrre Thalberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9892015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110379(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1110379T1 publication Critical patent/CY1110379T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Abstract

Η εφεύρεση αναφέρεται σε νέα φαρμακευτική σύνθεση χρήσιμη στη θεραπευτική αντιμετώπιση των αναπνευστικών διαταραχών όπως άσθμα, ρινίτιδα και χρόνια αποφρακτική πνευμονική νόσος (COPD).
CY20081100387T 2000-05-19 2008-04-09 Συνθεση που περιλαμβανει φορμοτερολη και ενα γλυκοκορτικοστεροειδες CY1110379T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0012260.6A GB0012260D0 (en) 2000-05-19 2000-05-19 Novel composition
EP04007922A EP1462100B1 (en) 2000-05-19 2001-05-17 Composition comprising formoterol and a glucocorticosteroid

Publications (1)

Publication Number Publication Date
CY1110379T1 true CY1110379T1 (el) 2015-04-29

Family

ID=9892015

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100387T CY1110379T1 (el) 2000-05-19 2008-04-09 Συνθεση που περιλαμβανει φορμοτερολη και ενα γλυκοκορτικοστεροειδες

Country Status (22)

Country Link
US (2) US6869942B2 (el)
EP (3) EP1977740A1 (el)
JP (3) JP5663125B2 (el)
KR (1) KR100799432B1 (el)
CN (1) CN100384408C (el)
AT (2) ATE274345T1 (el)
AU (2) AU2001259007B2 (el)
BR (1) BR0110946A (el)
CA (1) CA2409665C (el)
CY (1) CY1110379T1 (el)
DE (2) DE60132828T2 (el)
DK (2) DK1289506T3 (el)
ES (2) ES2298643T3 (el)
GB (1) GB0012260D0 (el)
IL (1) IL152470A0 (el)
MX (1) MXPA02011311A (el)
NO (1) NO333899B1 (el)
NZ (1) NZ522420A (el)
PT (2) PT1289506E (el)
SI (1) SI1289506T1 (el)
WO (1) WO2001089492A1 (el)
ZA (1) ZA200208709B (el)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
SE0200312D0 (sv) * 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
JP4744876B2 (ja) * 2002-08-21 2011-08-10 ノートン・ヘルスケアー リミテッド 乾燥粉末吸入組成物の製造方法
GB0219512D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
WO2004030659A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
CA2533887A1 (en) * 2003-09-30 2005-04-14 Acusphere, Inc. Injectable, oral, or topical sustained release pharmaceutical formulations
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
JP2007513139A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 安定性の改善した多粒子組成物
US20050277602A1 (en) * 2004-05-21 2005-12-15 Grunstein Michael M Methods employing agonists of P38 map kinase for the treatment of asthma
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
EP1848444B1 (en) 2005-02-10 2016-11-09 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
JP5095615B2 (ja) * 2005-06-27 2012-12-12 バリアント・インターナショナル・（バルバドス）・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ ブプロピオン塩の放出調整製剤
BRPI0613034A8 (pt) 2005-07-14 2018-01-02 Lipothera Inc formulação injetável para acúmulo de tecido adiposo, formulação injetável e método para o tratamento de acúmulo de gordura, e, método para reduzir o tecido adiposo.
TW200738635A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200734305A (en) * 2005-08-02 2007-09-16 Astrazeneca Ab New salt III
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
PL2077830T3 (pl) * 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
EP2022796A1 (en) * 2007-08-07 2009-02-11 Nycomed GmbH Amorphous ciclesonide
CN101474191B (zh) * 2009-01-21 2011-03-23 李虎山 一种治疗哮喘和慢性阻塞性肺病的药物组合物
EP2221048A1 (en) * 2009-02-18 2010-08-25 Siegfried Generics International AG Pharmaceutical composition for inhalation
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
AU2011205646B2 (en) * 2010-01-15 2014-10-02 Neothetics, Inc. Lyophilized cake formulations
PL2538922T3 (pl) 2010-02-25 2016-11-30 Formułowanie kompozycji do leczenia stanów zapalnych
CA2815374A1 (en) 2010-11-24 2012-06-07 Lithera, Inc. Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
WO2013091006A1 (en) * 2011-12-23 2013-06-27 Monash University Process for dry powder blending
UA118861C2 (uk) * 2013-12-06 2019-03-25 Оріон Корпорейшн Спосіб отримання сухих порошкових композицій для інгаляцій
KR20160038767A (ko) * 2014-09-30 2016-04-07 한미약품 주식회사 복합 활성성분의 안정성이 개선된 흡입 제형용 건조분말
AU2020356243A1 (en) 2019-09-24 2022-03-24 Chiesi Farmaceutici S.P.A. Novel carrier particles for dry powder formulations for inhalation
WO2023128918A1 (en) * 2021-12-31 2023-07-06 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process including a feeding gas system for preparing dry powder inhalation compositions
CN115364075B (zh) * 2022-09-16 2023-11-10 苏州易合医药有限公司 一种吸入颗粒组合物及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
AU673660C (en) * 1991-12-18 2002-07-25 Astrazeneca Ab New combination of formoterol and budesonide
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
SE9603669D0 (sv) * 1996-10-08 1996-10-08 Astra Ab New combination
DK0938467T3 (da) * 1996-11-11 2002-10-07 Sepracor Inc Fremgangsmåde til fremstilling af optisk rene isomerer af formoterol
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
IT1302657B1 (it) * 1998-10-13 2000-09-29 Farmabios Srl Processo stereoselettivo per la preparazione di budesonide nella formadi epimero 22-r.
DK1283036T3 (da) 1998-11-13 2008-03-25 Jagotec Ag Törpulver til inhalation
GB9903759D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900834D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
DE19947235A1 (de) * 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und beta¶2¶-Adrenorezeptor-Agonisten
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009591D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medical combinations
GB0009607D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medical compositions
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition

Also Published As

Publication number Publication date
NZ522420A (en) 2004-04-30
US7354913B2 (en) 2008-04-08
KR100799432B1 (ko) 2008-01-30
ATE385788T1 (de) 2008-03-15
JP2003534273A (ja) 2003-11-18
NO333899B1 (no) 2013-10-14
DE60105147D1 (de) 2004-09-30
US6869942B2 (en) 2005-03-22
DE60132828T2 (de) 2009-03-05
JP2012184271A (ja) 2012-09-27
CA2409665A1 (en) 2001-11-29
AU5900701A (en) 2001-12-03
PT1462100E (pt) 2008-04-18
PT1289506E (pt) 2004-12-31
DK1289506T3 (da) 2004-11-15
US20030236238A1 (en) 2003-12-25
IL152470A0 (en) 2003-06-24
EP1289506B1 (en) 2004-08-25
BR0110946A (pt) 2003-04-29
CA2409665C (en) 2010-03-30
GB0012260D0 (en) 2000-07-12
DE60132828D1 (de) 2008-03-27
NO20025221D0 (no) 2002-10-31
WO2001089492A1 (en) 2001-11-29
KR20030001515A (ko) 2003-01-06
EP1462100A1 (en) 2004-09-29
JP5663125B2 (ja) 2015-02-04
MXPA02011311A (es) 2003-04-25
US20050207989A1 (en) 2005-09-22
JP2015038118A (ja) 2015-02-26
CN1430508A (zh) 2003-07-16
EP1977740A1 (en) 2008-10-08
ZA200208709B (en) 2004-02-10
NO20025221L (no) 2002-10-31
AU2001259007B2 (en) 2005-11-17
ES2223844T3 (es) 2005-03-01
ATE274345T1 (de) 2004-09-15
CN100384408C (zh) 2008-04-30
ES2298643T3 (es) 2008-05-16
SI1289506T1 (en) 2005-02-28
EP1462100B1 (en) 2008-02-13
EP1289506A1 (en) 2003-03-12
DK1462100T3 (da) 2008-05-26
DE60105147T2 (de) 2005-09-08

Similar Documents

Publication Publication Date Title
CY1110379T1 (el) Συνθεση που περιλαμβανει φορμοτερολη και ενα γλυκοκορτικοστεροειδες
NO20025220L (no) Ny fremgangsmåte
HUS1900056I1 (hu) Légzési rendellenességek kezelésére alkalmas, glikopirrolát tartalmú száraz porkészítményt tartalmazó inhaláló készülék és alkalmazása
RS20060291A (en) Novel crystalline anhydride with anticholinergic effect
SE9900833D0 (sv) Novel combination
RS20060293A (en) Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same
SG137859A1 (en) Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
MXPA04007294A (es) Composicion para inhalacion.
SE9900834D0 (sv) Novel combination